Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review.

PLoS One 2012 7;7(11):e48877. Epub 2012 Nov 7.

Unit of Biomarkers and Susceptibility (UBS), Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), and CIBERESP, L'Hospitalet de Llobregat, Barcelona, Spain.

Introduction: The traditional staging system is inadequate to identify those patients with stage II colorectal cancer (CRC) at high risk of recurrence or with stage III CRC at low risk. A number of gene expression signatures to predict CRC prognosis have been proposed, but none is routinely used in the clinic. The aim of this work was to assess the prediction ability and potential clinical usefulness of these signatures in a series of independent datasets.

Methods: A literature review identified 31 gene expression signatures that used gene expression data to predict prognosis in CRC tissue. The search was based on the PubMed database and was restricted to papers published from January 2004 to December 2011. Eleven CRC gene expression datasets with outcome information were identified and downloaded from public repositories. Random Forest classifier was used to build predictors from the gene lists. Matthews correlation coefficient was chosen as a measure of classification accuracy and its associated p-value was used to assess association with prognosis. For clinical usefulness evaluation, positive and negative post-tests probabilities were computed in stage II and III samples.

Results: Five gene signatures showed significant association with prognosis and provided reasonable prediction accuracy in their own training datasets. Nevertheless, all signatures showed low reproducibility in independent data. Stratified analyses by stage or microsatellite instability status showed significant association but limited discrimination ability, especially in stage II tumors. From a clinical perspective, the most predictive signatures showed a minor but significant improvement over the classical staging system.

Conclusions: The published signatures show low prediction accuracy but moderate clinical usefulness. Although gene expression data may inform prognosis, better strategies for signature validation are needed to encourage their widespread use in the clinic.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048877PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492249PMC
May 2013
12 Reads
31 Citations
3.234 Impact Factor

Publication Analysis

Top Keywords

gene expression
24
expression signatures
12
stage iii
8
association prognosis
8
signatures low
8
colorectal cancer
8
prediction accuracy
8
gene
8
signatures
8
expression data
8
expression
6
crc
5
clinical
5
stage
5
prognosis
5
assess association
4
p-value assess
4
measure classification
4
chosen measure
4
classification accuracy
4

References

(Supplied by CrossRef)
Adjuvant treatment of colorectal cancer
LB Saltz et al.
Annu Rev Med 1997
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
J Clin Oncol 2004
A clinical risk score to predict 3-, 5- and 10-year survival in patients undergoing surgery for Dukes B colorectal cancer. Br J Cancer
DC McMillan et al.
2010
Molecular determinants of colon cancer metastasis
CA Portera Jr et al.
Surg Oncol 1998
Profiling the cancer genome
PA Cowin et al.
Annu Rev Genomics Hum Genet 2010

Similar Publications